Opinion|Videos|March 5, 2026
The SENTRY Trial: Selinexor Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
Author(s)Prithviraj Bose, MD, Pankit Vachhani, MD
Prithviraj Bose, MD, and Pankit Vachhani, MD, overview the phase 3 SENTRY trial evaluating selinexor plus ruxolitinib in JAK inhibitor–naive myelofibrosis
Advertisement
Episodes in this series
Prithviraj Bose, MD, and Pankit Vachhani, MD, provide an overview of the phase 3 SENTRY trial (NCT04562389) evaluating selinexor (Xpovio) plus ruxolitinib (Jakafi) vs placebo plus ruxolitnib in patients with JAK inhibitor–naive myelofibrosis. Bose outlines the study design, patient population, and rationale for combining these agents in the frontline setting. Vachhani discusses how this trial aims to determine whether combination therapy can improve spleen volume reduction and symptom outcomes compared with standard JAK inhibitor therapy alone.
Advertisement
Related to this article
Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.
Andrew Kuykendall, MD, discusses the FDA approval of rusfertide and how to apply it in clinical practice for polycythemia vera management.
An NDA seeks FDA approval of savolitinib plus osimertinib for EGFR-mutated NSCLC with MET overexpression or amplification after EGFR TKI therapy.
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
The NMPA has approved of pirtobrutinib in treatment-naive and previously treated CLL/SLL.
Roswell Park Comprehensive Cancer Center recognized members of its clinical, research and healthcare teams during the second annual Excellence Awards.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
China's NMPA Approves Pirtobrutinib Across CLL
3
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5